Q4 revenue -- $67.3 million reported for the quarter ended Dec. 31, 2025, compared to $1.5 million in Q4 2024; increase driven primarily by AstraZeneca and Gilead (NASDAQ:GILD) payments. Full-year ...
Discover how to access company financial reports and SEC filings through investor relations sections and the EDGAR database for informed investing.
Proof-of-activity is a blockchain consensus that combines proof-of-work and proof-of-stake to enhance security and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results